---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-25-000030"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:43:39.290604+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gilead Q2: revenue $7.1B, Biktarvy +9%, product sales ex-Veklury +4%; FY guidance raised

## Summary
- Revenue $7.1B (+2% YoY), product sales ex-Veklury $6.9B (+4%); Biktarvy $3.5B (+9%).
- GAAP diluted EPS $1.56 vs $1.29 YoY; non-GAAP diluted EPS $2.01, flat YoY.
- FY2025 guidance raised: product sales $28.3-28.7B, diluted EPS $5.85-6.15, non-GAAP EPS $7.95-8.25.
- HIV sales +7% to $5.1B; Trodelvy +14% to $364M; Cell therapy -7% to $485M.
- FDA approved Yeztugo as first twice-yearly HIV prevention; MYR impairment $190M.

## SEC filing metadata
- accession: 0000882095-25-000030
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209525000030/0000882095-25-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209525000030/gild-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-25-000030
- JSON: https://secwatch.observer/filing/0000882095-25-000030.json
- Plain text: https://secwatch.observer/filing/0000882095-25-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.